2023 World Conference on Lung Cancer (Posters)-P1.06. NIR-II Mediates Non-small Cell Lung Cancer Nanovaccines for Targeted Lymph Node Delivery and Anti-tumor Immune Activation

P1.06. NIR-II Mediates Non-small Cell Lung Cancer Nanovaccines for Targeted Lymph Node Delivery and Anti-tumor Immune Activation - PDF(Slides)

Back to course

Pdf Summary

Researchers in China presented a study on a potential therapy for non-small cell lung cancer (NSCLC) at the IASLC 2023 World Conference on Lung Cancer. The study focused on the development of personalized cancer nano-vaccines for targeted lymph node delivery and anti-tumor immune activation. The researchers proposed a strategy that involved converting primary tumors into antigens using gold nanorods with a photothermal effect. These antigens, along with adjuvants, were then delivered to lymph nodes to produce personalized cancer nano-vaccines.<br /><br />To reduce toxicity, the gold nanorods were modified with PEG (polyethylene glycol). Nanoparticles loaded with an immunoadjuvant called R848 were prepared using a single emulsification method. The nanoparticles were characterized, and the photothermal properties of the gold nanorods were investigated.<br /><br />Cellular level experiments confirmed the uptake of the nanoparticles by BMDC cells and verified their toxicity. Antigen capture and in vivo therapy experiments are currently underway.<br /><br />The study demonstrated that the nano-vaccines programmed by the gold nanorods and R848-loaded nanoparticles exhibited potent anti-tumor effects against NSCLC cells. The nano-vaccines also showed favorable safety to dendritic cells (DC) and bone marrow-derived dendritic cells (BMDC). Mature DCs were induced by the treatment in vitro.<br /><br />The researchers also demonstrated the ability of the R848-loaded nanoparticles to capture tumor antigens. This study provided a modular strategy to enhance the antitumor immunity of cancer vaccines, which could activate the host's own immune system and work synergistically with immune checkpoint blockade (ICB) antibodies.<br /><br />The work was supported by various funding sources, including the Natural Science Foundation of Guangdong and the Science and Technology Program of Guangzhou.

Asset Subtitle

Haiyu Zhou

Meta Tag

Speaker Haiyu Zhou

Topic Tumor Biology: Preclinical Biology - Tumor Immunity

Keywords

non-small cell lung cancer

therapy

nano-vaccines

lymph node delivery

anti-tumor immune activation

gold nanorods

photothermal effect

PEG modification

immunoadjuvant

antigen capture